- WHO: The 2022 recommended influenza strains in southern hemisphere
- New COVID-19 variant: ETA appeared in at least 82 countries and regions
- Tumor microenvironment and drug resistance in immunotherapy
- Can Probiotics prevent Alzheimer’s disease as regulator of brain function?
- The nano antibody from alpaca effectively against COVID-19 and variants
- COVID-19 can’t escape by the new method of virus detection: DNA sensor
Tumor therapy has entered the age of immunotherapy
Tumor therapy has entered the age of immunotherapy. Major breakthroughs in liver cancer research Expert: Tumor therapy has entered the age of immunotherapy.
On December 23, 2020, the top international biological journal “Cell” published a blockbuster research result related to recurrent liver cancer. The team of Academician Fan Jia from the Institute of Liver Cancer of Fudan University (Zhongshan Hospital) and Shenzhen BGI Institute of Life Sciences The collaboration, using single-cell RNA sequencing technology, revealed the immune characteristics and tumor immune escape mechanisms of early recurrent liver cancer at the single-cell level.
It is reported that primary liver cancer, or liver cancer for short, is a high-incidence malignant tumor in some countries. Newly detected cases each year account for more than half of the world, and the fatality rate remains high. It has become a frontier hot spot in clinical tumor research. The incidence of recurrent liver cancer within 5 years after liver cancer surgery is as high as 60% to 70%, of which 2/3 relapse within 2 years after surgery (early recurrence), which has become a key factor affecting the prognosis of patients and is also a clinical research difficulty.
Needless to say, the theoretical contribution of this research to liver cancer immunotherapy, the microscopic process of the game between recurrent liver cancer tumor cells and the immune system revealed in it is even more exquisite as a spy battle.
On the surface, in recurrent liver cancer, the body’s ability to recognize and attack tumor cells should be stronger, and tumor cells are less likely to escape. But this obviously does not match the actual situation. The research team concluded that the tumor immune escape mechanism of recurrent liver cancer is different from that of primary liver cancer.
Later, the research team discovered that in recurrent liver cancer, the tumor cells were surprisingly cunning.
This research reveals the subtle battle between tumor cells and immune cells in recurrent liver cancer from the cellular level for the first time. It makes people sigh that tumor cells not only have a strong desire to survive, but also have a very intelligent survival mechanism. Single-cell sequencing technology provides a new tool for microscopic interpretation of cell behavior and immune mechanisms, enabling us to better understand the immune characteristics of recurring tumors, so that it is possible to better respond to tumor recurrence monitoring and medication.
Professor Fan Jia, an academician of the Chinese Academy of Sciences, said that cancer therapy has entered the era of immunotherapy. Research has systematically analyzed the immune microecological differences between primary and recurrent liver cancer at the single-cell level, and revealed the characteristic immune profile and immune escape mechanism of early recurring liver cancer. In order to further improve the efficacy of liver cancer immunotherapy and find effective new strategies for the prevention and treatment of liver cancer recurrence and metastasis, it will provide more theoretical basis and experimental evidence. It is hoped that more potential therapeutic targets will be discovered and the effect of “1+1 is greater than 2” in treatment.
(source:internet, reference only)